Journal of Clinical Medicine

Research

Jump to: Review

8 pages, 1158 KiB

Open AccessArticle

Longitudinal Analysis and Comparison of Six Serological Assays up to Eight Months Post-COVID-19 Diagnosis

by Aurélien Aubry, Baptiste Demey, Catherine François, Gilles Duverlie, Sandrine Castelain, François Helle and Etienne Brochot

J. Clin. Med. 2021, 10(9), 1815; https://doi.org/10.3390/jcm10091815 - 21 Apr 2021

Cited by 8 | Viewed by 1799

Abstract

Background: There is much data available concerning the initiation of the immune response after SARS-CoV-2 infection, but long-term data are scarce. Methods: We thus longitudinally evaluated and compared the total and neutralizing immune response of 61 patients to SARS-CoV-2 infection up to eight [...] Read more.

Background: There is much data available concerning the initiation of the immune response after SARS-CoV-2 infection, but long-term data are scarce. Methods: We thus longitudinally evaluated and compared the total and neutralizing immune response of 61 patients to SARS-CoV-2 infection up to eight months after diagnosis by RT–PCR using several commercial assays. Results: Among the 208 samples tested, the percentage of seropositivity was comparable between assays up to four months after diagnosis and then tended to be more heterogeneous between assays (p < 0.05). The percentage of patients with a neutralizing titer decreased from 82% before two months postdiagnosis to 57% after six months. This decrease appeared to be more marked for patients under 65 years old and those not requiring hospitalization. The percentage of serology reversion at 6 months was from 11% with the WANTAI total assay to over 39% with the ABBOTT IgG assay. The neutralizing antibody titers decreased in parallel with the decrease of total antibody titers, with important heterogeneity between assays. Conclusions: In conclusion, serological tests show equivalent sensitivity in the first months after the diagnosis of SARS-CoV-2 infection, but their performance later, postinfection, must be considered when interpreting the results. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

23 pages, 2181 KiB

Open AccessArticle

Comorbidities and Susceptibility to COVID-19: A Generalized Gene Set Data Mining Approach

by Micaela F. Beckman, Farah Bahrani Mougeot and Jean-Luc C. Mougeot

J. Clin. Med. 2021, 10(8), 1666; https://doi.org/10.3390/jcm10081666 - 13 Apr 2021

Cited by 11 | Viewed by 4960

Abstract

The COVID-19 pandemic has led to over 2.26 million deaths for almost 104 million confirmed cases worldwide, as of 4 February 2021 (WHO). Risk factors include pre-existing conditions such as cancer, cardiovascular disease, diabetes, and obesity. Although several vaccines have been deployed, there [...] Read more.

The COVID-19 pandemic has led to over 2.26 million deaths for almost 104 million confirmed cases worldwide, as of 4 February 2021 (WHO). Risk factors include pre-existing conditions such as cancer, cardiovascular disease, diabetes, and obesity. Although several vaccines have been deployed, there are few alternative anti-viral treatments available in the case of reduced or non-existent vaccine protection. Adopting a long-term holistic approach to cope with the COVID-19 pandemic appears critical with the emergence of novel and more infectious SARS-CoV-2 variants. Our objective was to identify comorbidity-associated single nucleotide polymorphisms (SNPs), potentially conferring increased susceptibility to SARS-CoV-2 infection using a computational meta-analysis approach. SNP datasets were downloaded from a publicly available genome-wide association studies (GWAS) catalog for 141 of 258 candidate COVID-19 comorbidities. Gene-level SNP analysis was performed to identify significant pathways by using the program MAGMA. An SNP annotation program was used to analyze MAGMA-identified genes. Differential gene expression was determined for significant genes across 30 general tissue types using the Functional and Annotation Mapping of GWAS online tool GENE2FUNC. COVID-19 comorbidities (n = 22) from six disease categories were found to have significant associated pathways, validated by Q–Q plots (p < 0.05). Protein–protein interactions of significant (p < 0.05) differentially expressed genes were visualized with the STRING program. Gene interaction networks were found to be relevant to SARS and influenza pathogenesis. In conclusion, we were able to identify the pathways potentially affected by or affecting SARS-CoV-2 infection in underlying medical conditions likely to confer susceptibility and/or the severity of COVID-19. Our findings have implications in future COVID-19 experimental research and treatment development. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

13 pages, 2521 KiB

Open AccessFeature PaperArticle

Skin Manifestation of SARS-CoV-2: The Italian Experience

by Gerardo Cazzato, Caterina Foti, Anna Colagrande, Antonietta Cimmino, Sara Scarcella, Gerolamo Cicco, Sara Sablone, Francesca Arezzo, Paolo Romita, Teresa Lettini, Leonardo Resta and Giuseppe Ingravallo

J. Clin. Med. 2021, 10(8), 1566; https://doi.org/10.3390/jcm10081566 - 8 Apr 2021

Cited by 14 | Viewed by 5139

Abstract

At the end of December 2019, a new coronavirus denominated Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was identified in Wuhan, Hubei province, China. Less than three months later, the World Health Organization (WHO) declared coronavirus disease-19 (COVID-19) to be a global pandemic. [...] Read more.

At the end of December 2019, a new coronavirus denominated Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was identified in Wuhan, Hubei province, China. Less than three months later, the World Health Organization (WHO) declared coronavirus disease-19 (COVID-19) to be a global pandemic. Growing numbers of clinical, histopathological, and molecular findings were subsequently reported, among which a particular interest in skin manifestations during the course of the disease was evinced. Today, about one year after the development of the first major infectious foci in Italy, various large case series of patients with COVID-19-related skin manifestations have focused on skin specimens. However, few are supported by histopathological, immunohistochemical, and polymerase chain reaction (PCR) data on skin specimens. Here, we present nine cases of COVID-positive patients, confirmed by histological, immunophenotypical, and PCR findings, who underwent skin biopsy. A review of the literature in Italian cases with COVID-related skin manifestations is then provided. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

13 pages, 1598 KiB

Open AccessArticle

Early Prognostic Indicators of Subsequent Hospitalization in Patients with Mild COVID-19

by Alyssa Ylescupidez, Aaron Rips, Henry T. Bahnson, Cate Speake, Punam Verma, Anne M. Hocking, Jane H. Buckner and Uma Malhotra

J. Clin. Med. 2021, 10(8), 1562; https://doi.org/10.3390/jcm10081562 - 8 Apr 2021

Cited by 1 | Viewed by 2391

Abstract

Comprehensive data on early prognostic indicators in patients with mild COVID-19 remains sparse. In this single center case series, we characterized the initial clinical presentation in 180 patients with mild COVID-19 and defined the earliest predictors of subsequent deterioration and need for hospitalization. [...] Read more.

Comprehensive data on early prognostic indicators in patients with mild COVID-19 remains sparse. In this single center case series, we characterized the initial clinical presentation in 180 patients with mild COVID-19 and defined the earliest predictors of subsequent deterioration and need for hospitalization. Three broad patient phenotypes and four symptom clusters were characterized, differentiated by varying risk for adverse outcomes. Among 14 symptoms assessed, subjective shortness of breath (SOB) most strongly associated with adverse outcomes (odds ratio (OR) 21.3, 95% confidence interval (CI): 2.7–166.4; p < 0.0001). In combination, SOB and number of comorbidities were highly predictive of subsequent hospitalization (area under the curve (AUC) 92%). Additionally, initial lymphopenia (OR 21.0, 95% CI: 2.1–210.1; p = 0.002) and male sex (OR 3.5, 95% CI: 0.9–13.0; p = 0.05) were associated with increased risk of poor outcomes. Patients with known comorbidities, especially multiple, and those presenting with subjective SOB or lymphopenia should receive close monitoring and consideration for preemptive treatment, even when presenting with mild symptoms. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

17 pages, 298 KiB

Open AccessArticle

Trends of COVID-19 Admissions in an Italian Hub during the Pandemic Peak: Large Retrospective Study Focused on Older Subjects

by Andrea Ticinesi, Antonio Nouvenne, Nicoletta Cerundolo, Alberto Parise, Beatrice Prati, Angela Guerra and Tiziana Meschi

J. Clin. Med. 2021, 10(5), 1115; https://doi.org/10.3390/jcm10051115 - 7 Mar 2021

Cited by 11 | Viewed by 2590

Abstract

Older multimorbid frail subjects have been severely involved in the coronavirus disease-19 (COVID-19) pandemic. The aim of this retrospective study is to compare the clinical features and outcomes of patients admitted in different phases of the outbreak in a COVID-19 hospital hub, with [...] Read more.

Older multimorbid frail subjects have been severely involved in the coronavirus disease-19 (COVID-19) pandemic. The aim of this retrospective study is to compare the clinical features and outcomes of patients admitted in different phases of the outbreak in a COVID-19 hospital hub, with a particular focus on age, multimorbidity, and functional dependency. The clinical records of 1264 patients with clinical and radiological features compatible with COVID-19 pneumonia admitted in February–June, 2020, were analyzed, retrieving demographical, clinical, laboratory data, and outcomes. All variables were compared after stratification by the period of admission (first phase: rising slope of pandemic wave; second phase: plateau and falling slope), age, results of the first reverse transcriptase-polymerase chain reaction (RT-PCR) test for detection of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), multimorbidity (≥2 chronic diseases), and presence of disability. Factors independently associated with hospital mortality were determined by multivariate forward-selection logistic regression. Patients admitted during the second phase were older, more frequently multimorbid, disabled, and of female gender. However, on admission they exhibited milder respiratory impairment (PaO₂/FiO₂ 268, IQR 174–361, vs. 238, IQR 126–327 mmHg, p < 0.001) and lower mortality (22% vs. 27%, p < 0.001). Age, respiratory exchanges, positive RT-PCR test, number of chronic diseases (odds ratio (OR) 1.166, 95% confidence interval (CI) 1.036–1.313, p = 0.011), and disability (OR 1.927, 95% CI 1.027–3.618, p = 0.022) were positively associated with mortality, while admission during the second phase exhibited an inverse association (OR 0.427, 95% CI 0.260–0.700, p = 0.001). In conclusion, older multimorbid patients were mainly hospitalized during the second phase of the pandemic wave. The prognosis was strongly influenced by the COVID-19 phenotype and period of admission, not just by age, multimorbidity, and disability. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

12 pages, 563 KiB

Open AccessArticle

Prognostic Factors at Admission for In-Hospital Mortality from COVID-19 Infection in an Older Rural Population in Central Spain

by Modesto M. Maestre-Muñiz, Ángel Arias, Laura Arias-González, Basilio Angulo-Lara and Alfredo J. Lucendo

J. Clin. Med. 2021, 10(2), 318; https://doi.org/10.3390/jcm10020318 - 16 Jan 2021

Cited by 8 | Viewed by 3007

Abstract

Background: Risk factors for in-hospital mortality from severe coronavirus disease 2019 (COVID-19) infection have been identified in studies mainly carried out in urban-based teaching hospitals. However, there is little data for rural populations attending community hospitals during the first wave of the pandemic. [...] Read more.

Background: Risk factors for in-hospital mortality from severe coronavirus disease 2019 (COVID-19) infection have been identified in studies mainly carried out in urban-based teaching hospitals. However, there is little data for rural populations attending community hospitals during the first wave of the pandemic. Methods: A retrospective, single-center cohort study was undertaken among inpatients at a rural community hospital in Spain. Electronic medical records of the 444 patients (56.5% males) admitted due to severe SARS-CoV-2 infection during 26 February 2020–31 May 2020 were reviewed. Results: Mean age was 71.2 ± 14.6 years (rank 22–98), with 69.8% over 65. At least one comorbidity was present in 410 patients (92.3%), with chronic obstructive pulmonary disease (COPD) present in 21.7%. Overall in-hospital mortality was 32%. Multivariate analysis of factors associated with death identified patients’ age (with a cumulative effect per decade), COPD as a comorbidity, and respiratory insufficiency at the point of admission. No additional comorbid conditions proved significant. Among analytical values, increased serum creatinine, LDH > 500 mg/dL, thrombocytopenia (<150 × 10⁹/per L), and lymphopenia (<1000 cells/µL) were all independently associated with mortality during admission. Conclusions: Age remained the major determinant for COVID-19-caused mortality; COPD was the only comorbidity independently associated with in-hospital death, together with respiratory insufficiency and analytical markers at admission. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

10 pages, 686 KiB

Open AccessArticle

Head-to-Head Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-CoV-2 Infection

by Julien Favresse, Constant Gillot, Maxime Oliveira, Julie Cadrobbi, Marc Elsen, Christine Eucher, Kim Laffineur, Catherine Rosseels, Sandrine Van Eeckhoudt, Jean-Baptiste Nicolas, Laure Morimont, Jean-Michel Dogné and Jonathan Douxfils

J. Clin. Med. 2021, 10(2), 265; https://doi.org/10.3390/jcm10020265 - 13 Jan 2021

Cited by 67 | Viewed by 8825

Abstract

(1) Background: The detection of SARS-CoV-2 RNA in nasopharyngeal samples through real-time reverse transcription-polymerase chain reaction (RT-PCR) is considered the standard gold method for the diagnosis of SARS-CoV-2 infection. Antigen detection (AD) tests are more rapid, less laborious, and less expensive alternatives but [...] Read more.

(1) Background: The detection of SARS-CoV-2 RNA in nasopharyngeal samples through real-time reverse transcription-polymerase chain reaction (RT-PCR) is considered the standard gold method for the diagnosis of SARS-CoV-2 infection. Antigen detection (AD) tests are more rapid, less laborious, and less expensive alternatives but still require clinical validation. (2) Methods: This study compared the clinical performance of five AD tests, including four rapid AD (RAD) tests (biotical, Panbio, Healgen, and Roche) and one automated AD test (VITROS). For that purpose, 118 (62.8%) symptomatic patients and 70 (37.2%) asymptomatic subjects were tested, and results were compared to RT-PCR. (3) Results: The performance of the RAD tests was modest and allowed us to identify RT-PCR positive patients with higher viral loads. For Ct values ≤25, the sensitivity ranged from 93.1% (95% CI: 83.3–98.1%) to 96.6% (95% CI: 88.1–99.6%), meaning that some samples with high viral loads were missed. Considering the Ct value proposed by the CDC for contagiousness (i.e., Ct values ≤33) sensitivities ranged from 76.2% (95% CI: 65.4–85.1%) to 88.8% (95% CI: 79.7–94.7%) while the specificity ranged from 96.3% (95% CI: 90.8–99.0%) to 99.1% (95% CI: 95.0–100%). The VITROS automated assay showed a 100% (95% CI: 95.5–100%) sensitivity for Ct values ≤33, and had a specificity of 100% (95% CI: 96.6–100%); (4) Conclusions: Compared to RAD tests, the VITROS assay fully aligned with RT-PCR for Ct values up to 33, which might allow a faster, easier and cheaper identification of SARS-CoV-2 contagious patients. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

9 pages, 257 KiB

Open AccessArticle

Evidence of Pulmonary Hypertension after SARS-CoV-2 Infection in Subjects without Previous Significant Cardiovascular Pathology

by Cristina Tudoran, Mariana Tudoran, Voichita Elena Lazureanu, Adelina Raluca Marinescu, Gheorghe Nicusor Pop, Alexandru Silvius Pescariu, Alexandra Enache and Talida Georgiana Cut

J. Clin. Med. 2021, 10(2), 199; https://doi.org/10.3390/jcm10020199 - 7 Jan 2021

Cited by 50 | Viewed by 4544

Abstract

Background: Coronavirus (Covid-19) infection represents a serious medical condition, often associated with cardiovascular complications, pulmonary hypertension (PH), and right ventricle dysfunction (RVD). The aim of this study is to show, by means of transthoracic echocardiography (TTE), the presence of an increased estimated systolic [...] Read more.

Background: Coronavirus (Covid-19) infection represents a serious medical condition, often associated with cardiovascular complications, pulmonary hypertension (PH), and right ventricle dysfunction (RVD). The aim of this study is to show, by means of transthoracic echocardiography (TTE), the presence of an increased estimated systolic pressure in the pulmonary artery (esPAP) and altered right ventricular global longitudinal strain (RV-GLS) in patients without history of PH. Methods: In a group of 91 patients, aged under 55 years, hospitalized for a moderate Covid-19 infection, a thorough cardiologic and TTE examination were performed two months after discharge. Their initial thorax computer-tomography (TCT) images and laboratory data were accessed from the electronic data base of the hospital. Results: We observed an increased prevalence of PH (7.69%) and RVD (10.28%), significantly correlated with the initial levels of the TCT score and inflammatory factors (p ˂ 0.001), but borderline changes were observed in more patients. Multivariate regression analysis showed that these factors and RV-GLS explain 89.5% of elevated esPAP. Conclusions: In COVID-19 infection, PH and RVD are common complications, being encountered after the recovery even in moderate cases. It appears to be a connection between their severity and the extent of the initial pulmonary injury and of the inflammatory response. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

13 pages, 613 KiB

Open AccessCommunication

Prognostic Factors of COVID-19 Infection in Elderly Patients: A Multicenter Study

by Jihye Hwang, Ho-Sung Ryu, Hyun Ah Kim, Miri Hyun, Ji Yeon Lee and Hyon-Ah Yi

J. Clin. Med. 2020, 9(12), 3932; https://doi.org/10.3390/jcm9123932 - 4 Dec 2020

Cited by 24 | Viewed by 3797

Abstract

The outbreak of the COVID-19 pandemic is a substantial threat to the health of all populations worldwide, and old age is a robust risk factor for poor prognosis of COVID-19 infection. To reduce the fatality rate of COVID-19 infection, further understanding of elderly [...] Read more.

The outbreak of the COVID-19 pandemic is a substantial threat to the health of all populations worldwide, and old age is a robust risk factor for poor prognosis of COVID-19 infection. To reduce the fatality rate of COVID-19 infection, further understanding of elderly patients with COVID-19 is necessary. We aimed to investigate the prognostic factors in elderly patients with COVID-19. This was a multicenter and retrospective study. Overall, 340 elderly patients with COVID-19 were enrolled in 3 hospitals in Daegu, South Korea. Death and severe pneumonia requiring oxygen treatment were defined as poor clinical outcomes. Of the patients studied, 15% died and 35.2% were classified as having severe pneumonia. In binary logistic regression analysis, activities of daily living (ADL) impairment, fever during hospitalization, initial infiltration on chest radiograph, and initial increased C-reactive protein (CRP) were significantly associated with severe pneumonia (OR = 5.33, p < 0.001; OR = 3.2, p = 0.002; OR = 2.32, p = 0.044; and OR = 1.33, p < 0.001, respectively). ADL impairment, comorbidity, fever during hospitalization, and initial increased CRP were significantly associated with death (OR = 7.13, p < 0.001; OR = 3.28, p = 0.005; OR = 3.15, p = 0.032, and OR = 1.18, p < 0.001, respectively). ADL impairment, fever, and initial CRP were poor prognostic factors in elderly patients with COVID-19. Understanding these poor prognostic factors is necessary to control the disease in elderly patients. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

12 pages, 2363 KiB

Open AccessArticle

Serological Surveillance of COVID-19 Hospitalized Patients in Réunion Island (France) Revealed that Specific Immunoglobulin G Are Rapidly Vanishing in Severe Cases

by Anthony Dobi, Anne-Laure Sandenon Seteyen, Mahary Lalarizo Rakoto, Grégorie Lebeau, Damien Vagner, Étienne Frumence, Claude Giry, Axelle Septembre-Malaterre, Loïc Raffray and Philippe Gasque

J. Clin. Med. 2020, 9(12), 3847; https://doi.org/10.3390/jcm9123847 - 27 Nov 2020

Cited by 4 | Viewed by 2785

Abstract

Humoral immunity is critically important to control COVID-19. Long-term antibody responses remain to be fully characterized in hospitalized patients who have a high risk of death. We compared specific Immunoglobulin responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) between two groups, intensive [...] Read more.

Humoral immunity is critically important to control COVID-19. Long-term antibody responses remain to be fully characterized in hospitalized patients who have a high risk of death. We compared specific Immunoglobulin responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) between two groups, intensive care unit (ICU) and non-ICU hospitalized patients over several weeks. Plasma specific IgG, IgM, and IgA levels were assessed using a commercial ELISA and compared to an in-house cell-based ELISA. Among the patients analyzed (mean (SD) of age, 64.4 (15.9) years, 19.2% female), 12 (46.2%) were hospitalized in ICU. IgG levels increased in non-ICU cases from the second to the eighth week after symptom onset. By contrast, IgG response was blunted in ICU patients over the same period. ICU patients with hematological malignancies had very weak or even undetectable IgG levels. While both groups had comparable levels of specific IgM antibodies, we found much lower levels of specific IgA in ICU versus non-ICU patients. In conclusion, COVID-19 ICU patients may be at risk of reinfection as their specific IgG response is declining in a matter of weeks. Antibody neutralizing assays and studies on specific cellular immunity will have to be performed. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

29 pages, 7132 KiB

Open AccessArticle

ACE2 Interaction Networks in COVID-19: A Physiological Framework for Prediction of Outcome in Patients with Cardiovascular Risk Factors

by Zofia Wicik, Ceren Eyileten, Daniel Jakubik, Sérgio N. Simões, David C. Martins, Jr., Rodrigo Pavão, Jolanta M. Siller-Matula and Marek Postula

J. Clin. Med. 2020, 9(11), 3743; https://doi.org/10.3390/jcm9113743 - 21 Nov 2020

Cited by 74 | Viewed by 7402

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (coronavirus disease 2019; COVID-19) is associated with adverse outcomes in patients with cardiovascular disease (CVD). The aim of the study was to characterize the interaction between SARS-CoV-2 and Angiotensin-Converting Enzyme 2 (ACE2) functional networks [...] Read more.

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (coronavirus disease 2019; COVID-19) is associated with adverse outcomes in patients with cardiovascular disease (CVD). The aim of the study was to characterize the interaction between SARS-CoV-2 and Angiotensin-Converting Enzyme 2 (ACE2) functional networks with a focus on CVD. Methods: Using the network medicine approach and publicly available datasets, we investigated ACE2 tissue expression and described ACE2 interaction networks that could be affected by SARS-CoV-2 infection in the heart, lungs and nervous system. We compared them with changes in ACE-2 networks following SARS-CoV-2 infection by analyzing public data of human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). This analysis was performed using the Network by Relative Importance (NERI) algorithm, which integrates protein-protein interaction with co-expression networks. We also performed miRNA-target predictions to identify which miRNAs regulate ACE2-related networks and could play a role in the COVID19 outcome. Finally, we performed enrichment analysis for identifying the main COVID-19 risk groups. Results: We found similar ACE2 expression confidence levels in respiratory and cardiovascular systems, supporting that heart tissue is a potential target of SARS-CoV-2. Analysis of ACE2 interaction networks in infected hiPSC-CMs identified multiple hub genes with corrupted signaling which can be responsible for cardiovascular symptoms. The most affected genes were EGFR (Epidermal Growth Factor Receptor), FN1 (Fibronectin 1), TP53, HSP90AA1, and APP (Amyloid Beta Precursor Protein), while the most affected interactions were associated with MAST2 and CALM1 (Calmodulin 1). Enrichment analysis revealed multiple diseases associated with the interaction networks of ACE2, especially cancerous diseases, obesity, hypertensive disease, Alzheimer’s disease, non-insulin-dependent diabetes mellitus, and congestive heart failure. Among affected ACE2-network components connected with the SARS-Cov-2 interactome, we identified AGT (Angiotensinogen), CAT (Catalase), DPP4 (Dipeptidyl Peptidase 4), CCL2 (C-C Motif Chemokine Ligand 2), TFRC (Transferrin Receptor) and CAV1 (Caveolin-1), associated with cardiovascular risk factors. We described for the first time miRNAs which were common regulators of ACE2 networks and virus-related proteins in all analyzed datasets. The top miRNAs regulating ACE2 networks were miR-27a-3p, miR-26b-5p, miR-10b-5p, miR-302c-5p, hsa-miR-587, hsa-miR-1305, hsa-miR-200b-3p, hsa-miR-124-3p, and hsa-miR-16-5p. Conclusion: Our study provides a complete mechanistic framework for investigating the ACE2 network which was validated by expression data. This framework predicted risk groups, including the established ones, thus providing reliable novel information regarding the complexity of signaling pathways affected by SARS-CoV-2. It also identified miRNAs that could be used in personalized diagnosis in COVID-19. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

14 pages, 1044 KiB

Open AccessArticle

Hospital Resources May Be an Important Aspect of Mortality Rate among Critically Ill Patients with COVID-19: The Paradigm of Greece

by Christina Routsi, Eleni Magira, Stelios Kokkoris, Ilias Siembos, Charikleia Vrettou, Dimitris Zervakis, Eleni Ischaki, Sotiris Malahias, Ioanna Sigala, Andreas Asimakos, Theodora Daidou, Panagiotis Kaltsas, Evangelia Douka, Adamandia Sotiriou, Vassiliki Markaki, Prodromos Temberikidis, Apostolos Koroneos, Panagiotis Politis, Zafiria Mastora, Efrosini Dima, Theodoros Tsoutsouras, Ioannis Papahatzakis, Panagiota Gioni, Athina Strilakou, Aikaterini Maragouti, Eleftheria Mizi, Ageliki Kanavou, Aikaterini Sarri, Evdokia Gavrielatou, Spyros Mentzelopoulos, Ioannis Kalomenidis, Vassilios Papastamopoulos, Anastasia Kotanidou and Spyros Zakynthinos Show full author list Hide full author list

J. Clin. Med. 2020, 9(11), 3730; https://doi.org/10.3390/jcm9113730 - 20 Nov 2020

Cited by 11 | Viewed by 3350

Abstract

For critically ill patients with coronavirus disease 2019 (COVID-19) who require intensive care unit (ICU) admission, extremely high mortality rates (even 97%) have been reported. We hypothesized that overburdened hospital resources by the extent of the pandemic rather than the disease per se [...] Read more.

For critically ill patients with coronavirus disease 2019 (COVID-19) who require intensive care unit (ICU) admission, extremely high mortality rates (even 97%) have been reported. We hypothesized that overburdened hospital resources by the extent of the pandemic rather than the disease per se might play an important role on unfavorable prognosis. We sought to determine the outcome of such patients admitted to the general ICUs of a hospital with sufficient resources. We performed a prospective observational study of adult patients with COVID-19 consecutively admitted to COVID—designated ICUs at Evangelismos Hospital, Athens, Greece. Among 50 patients, ICU and hospital mortality was 32% (16/50). Median PaO₂/FiO₂ was 121 mmHg (interquartile range (IQR), 86–171 mmHg) and most patients had moderate or severe acute respiratory distress syndrome (ARDS). Hospital resources may be an important aspect of mortality rates, since severely ill COVID-19 patients with moderate and severe ARDS may have understandable mortality, provided that they are admitted to general ICUs without limitations on hospital resources. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

12 pages, 1278 KiB

Open AccessArticle

First Wave of COVID-19 in French Patients with Cystic Fibrosis

by Harriet Corvol, Sandra de Miranda, Lydie Lemonnier, Astrid Kemgang, Martine Reynaud Gaubert, Raphael Chiron, Marie-Laure Dalphin, Isabelle Durieu, Jean-Christophe Dubus, Véronique Houdouin, Anne Prevotat, Sophie Ramel, Marine Revillion, Laurence Weiss, Loic Guillot, Pierre-Yves Boelle and Pierre-Régis Burgel

J. Clin. Med. 2020, 9(11), 3624; https://doi.org/10.3390/jcm9113624 - 10 Nov 2020

Cited by 36 | Viewed by 4649

Abstract

Viral infections are known to lead to serious respiratory complications in cystic fibrosis (CF) patients. Hypothesizing that CF patients were a population at high risk for severe respiratory complications from SARS-CoV-2 infection, we conducted a national study to describe the clinical expression of [...] Read more.

Viral infections are known to lead to serious respiratory complications in cystic fibrosis (CF) patients. Hypothesizing that CF patients were a population at high risk for severe respiratory complications from SARS-CoV-2 infection, we conducted a national study to describe the clinical expression of COVID-19 in French CF patients. This prospective observational study involves all 47 French CF centers caring for approximately 7500 CF patients. Between March 1st and June 30th 2020, 31 patients were diagnosed with COVID-19: 19 had positive SARS-CoV-2 RT-PCR in nasopharyngeal swabs; 1 had negative RT-PCR but typical COVID-19 signs on a CT scan; and 11 had positive SARS-CoV-2 serology. Fifteen were males, median (range) age was 31 (9–60) years, and 12 patients were living with a lung transplant. The majority of the patients had CF-related diabetes (n = 19, 61.3%), and a mild lung disease (n = 19, 65%, with percent-predicted forced expiratory volume in 1 s (ppFEV₁) > 70). Three (10%) patients remained asymptomatic. For the 28 (90%) patients who displayed symptoms, most common symptoms at admission were fever (n = 22, 78.6%), fatigue (n = 14, 50%), and increased cough (n = 14, 50%). Nineteen were hospitalized (including 11 out of the 12 post-lung transplant patients), seven required oxygen therapy, and four (3 post-lung transplant patients) were admitted to an Intensive Care Unit (ICU). Ten developed complications (including acute respiratory distress syndrome in two post-lung transplant patients), but all recovered and were discharged home without noticeable short-term sequelae. Overall, French CF patients were rarely diagnosed with COVID-19. Further research should establish whether they were not infected or remained asymptomatic upon infection. In diagnosed cases, the short-term evolution was favorable with rare acute respiratory distress syndrome and no death. Post-lung transplant patients had more severe outcomes and should be monitored more closely. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

13 pages, 832 KiB

Open AccessArticle

Inhaled Corticosteroids and COVID-19 Risk and Mortality: A Nationwide Cohort Study

by Jae Chol Choi, Sun-Young Jung, Una A. Yoon, Seung-Hun You, Myo-Song Kim, Moon Seong Baek, Jae-Woo Jung and Won-Young Kim

J. Clin. Med. 2020, 9(11), 3406; https://doi.org/10.3390/jcm9113406 - 23 Oct 2020

Cited by 41 | Viewed by 5228

Abstract

Inhaled corticosteroids (ICS) could increase both the risk of coronavirus disease 2019 (COVID-19) and experiencing poor outcomes. To compare the clinical outcomes between ICS users and nonusers, COVID-19-related claims in the Korean Health Insurance Review and Assessment database were evaluated. To evaluate susceptibility [...] Read more.

Inhaled corticosteroids (ICS) could increase both the risk of coronavirus disease 2019 (COVID-19) and experiencing poor outcomes. To compare the clinical outcomes between ICS users and nonusers, COVID-19-related claims in the Korean Health Insurance Review and Assessment database were evaluated. To evaluate susceptibility to COVID-19 among patients with COPD or asthma, a nested case-control study was performed using the same database. In total, 7341 patients were confirmed to have COVID-19, including 114 ICS users and 7227 nonusers. Among 5910 patients who were hospitalized, death was observed for 9% of ICS users and 4% of nonusers. However, this association was not significant when adjusted for age, sex, region, comorbidities, and hospital type (aOR, 0.94; 95% CI, 0.43–2.07). The case-control analysis of COPD compared 640 cases with COVID-19 to 2560 matched controls without COVID-19, and the analysis of asthma compared 90 cases with COVID-19 to 360 matched controls without COVID-19. Use of ICS was not significantly associated with COVID-19 among patients with COPD (aOR, 1.02; 95% CI, 0.46–2.25) or asthma (aOR, 0.38; 95% CI, 0.13–1.17). Prior ICS use was not significantly associated with COVID-19 in patients with COPD or asthma, nor with clinical outcomes among patients with COVID-19. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

20 pages, 2905 KiB

Open AccessArticle

Presentation, Treatment Response and Short-Term Outcomes in Paediatric Multisystem Inflammatory Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS)

by Susanna Felsenstein, Emily Willis, Hannah Lythgoe, Liza McCann, Andrew Cleary, Kamran Mahmood, David Porter, Jessica Jones, Janet McDonagh, Alice Chieng, Giulia Varnier, Stephen Hughes, Mary Boullier, Fiona Ryan, Olumoyin Awogbemi, Giridhar Soda, Phuoc Duong, Clare Pain, Phil Riley and Christian M. Hedrich

J. Clin. Med. 2020, 9(10), 3293; https://doi.org/10.3390/jcm9103293 - 14 Oct 2020

Cited by 55 | Viewed by 7541

Abstract

The novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the pathogen responsible for Coronavirus Disease 2019 (COVID-19). Whilst most children and young people develop mild symptoms, recent reports suggest a novel paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS). Case definition [...] Read more.

The novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the pathogen responsible for Coronavirus Disease 2019 (COVID-19). Whilst most children and young people develop mild symptoms, recent reports suggest a novel paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS). Case definition and classification are preliminary, treatment is empiric and disease-associated outcomes are unclear. Here, we report 29 patients with PIMS-TS who were diagnosed, admitted and treated in the English North West between March and June 2020. Consistent with patterns observed internationally, cases peaked approximately 4 weeks after the initial surge of COVID-19-like symptoms in the UK population. Clinical symptoms included fever (100%), skin rashes (72%), cardiovascular involvement (86%), conjunctivitis (62%) and respiratory involvement (21%). Some patients had clinical features partially resembling Kawasaki disease (KD), toxic shock syndrome and cytokine storm syndrome. Male gender (69%), black, Asian and other minority ethnicities (BAME, 59%) were over-represented. Immune modulating treatment was used in all, including intravenous immunoglobulin (IVIG), corticosteroids and cytokine blockers. Notably, 32% of patients treated with IVIG alone went into remission. The rest required additional treatment, usually corticosteroids, with the exception of two patients who were treated with TNF inhibition and IL-1 blockade, respectively. Another patient received IL-1 inhibition as primary therapy, with associated rapid and sustained remission. Randomized and prospective studies are needed to investigate efficacy and safety of treatment, especially as resources of IVIG may be depleted secondary to high demand during future waves of COVID-19. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

12 pages, 1152 KiB

Open AccessFeature PaperArticle

Trajectories of Hospitalization in COVID-19 Patients: An Observational Study in France

by Pierre-Yves Boëlle, Tristan Delory, Xavier Maynadier, Cécile Janssen, Renaud Piarroux, Marie Pichenot, Xavier Lemaire, Nicolas Baclet, Pierre Weyrich, Hugues Melliez, Agnès Meybeck, Jean-Philippe Lanoix and Olivier Robineau

J. Clin. Med. 2020, 9(10), 3148; https://doi.org/10.3390/jcm9103148 - 29 Sep 2020

Cited by 39 | Viewed by 5221

Abstract

Describing the characteristics of COVID-19 patients in the hospital is of importance to assist in the management of hospital capacity in the future. Here, we analyze the trajectories of 1321 patients admitted to hospitals in northern and eastern France. We found that the [...] Read more.

Describing the characteristics of COVID-19 patients in the hospital is of importance to assist in the management of hospital capacity in the future. Here, we analyze the trajectories of 1321 patients admitted to hospitals in northern and eastern France. We found that the time from onset to hospitalization decreased with age, from 7.3 days in the 20–65 year-olds to 4.5 in the >80 year-olds (p < 0.0001). Overall, the length of stay in the hospital was 15.9 days, and the death rate was 20%. One patient out of four was admitted to the intensive care unit (ICU) for approximately one month. The characteristics of trajectories changed with age: fewer older patients were admitted to the ICU and the death rate was larger in the elderly. Admission shortly after onset was associated with increased mortality (odds-ratio (OR) = 1.8, Confidence Interval (CI) 95% [1.3, 2.6]) as well as male sex (OR = 2.1, CI 95% [1.5, 2.9]). Time from admission within the hospital to the transfer to ICU was short. The age- and sex-adjusted mortality rate decreased over the course of the epidemic, suggesting improvement in care over time. In the SARS-CoV-2 epidemic, the urgent need for ICU at admission and the prolonged length of stay in ICU are a challenge for bed management and organization of care. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

12 pages, 1438 KiB

Open AccessArticle

Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19

by Enrique Rodilla, Alberto Saura, Iratxe Jiménez, Andrea Mendizábal, Araceli Pineda-Cantero, Elizabeth Lorenzo-Hernández, Maria del Pilar Fidalgo-Montero, Joaquín Fernandez López-Cuervo, Ricardo Gil-Sánchez, Elisa Rabadán-Pejenaute, Lucy Abella-Vázquez, Vicente Giner-Galvañ, Marta Nataya Solís-Marquínez, Ramon Boixeda, Andrés de la Peña-Fernández, Francisco Javier Carrasco-Sánchez, Julio González-Moraleja, José David Torres-Peña, María Esther Guisado-Espartero, Joaquín Escobar-Sevilla, Marcos Guzmán-García, María Dolores Martín-Escalante, Ángel Luis Martínez-González, José Manuel Casas-Rojo and Ricardo Gómez-Huelgas Show full author list Hide full author list

J. Clin. Med. 2020, 9(10), 3136; https://doi.org/10.3390/jcm9103136 - 28 Sep 2020

Cited by 63 | Viewed by 11096

Abstract

It is unclear to which extent the higher mortality associated with hypertension in the coronavirus disease (COVID-19) is due to its increased prevalence among older patients or to specific mechanisms. Cross-sectional, observational, retrospective multicenter study, analyzing 12226 patients who required hospital admission in [...] Read more.

It is unclear to which extent the higher mortality associated with hypertension in the coronavirus disease (COVID-19) is due to its increased prevalence among older patients or to specific mechanisms. Cross-sectional, observational, retrospective multicenter study, analyzing 12226 patients who required hospital admission in 150 Spanish centers included in the nationwide SEMI-COVID-19 Network. We compared the clinical characteristics of survivors versus non-survivors. The mean age of the study population was 67.5 ± 16.1 years, 42.6% were women. Overall, 2630 (21.5%) subjects died. The most common comorbidity was hypertension (50.9%) followed by diabetes (19.1%), and atrial fibrillation (11.2%). Multivariate analysis showed that after adjusting for gender (males, OR: 1.5, p = 0.0001), age tertiles (second and third tertiles, OR: 2.0 and 4.7, p = 0.0001), and Charlson Comorbidity Index scores (second and third tertiles, OR: 4.7 and 8.1, p = 0.0001), hypertension was significantly predictive of all-cause mortality when this comorbidity was treated with angiotensin-converting enzyme inhibitors (ACEIs) (OR: 1.6, p = 0.002) or other than renin-angiotensin-aldosterone blockers (OR: 1.3, p = 0.001) or angiotensin II receptor blockers (ARBs) (OR: 1.2, p = 0.035). The preexisting condition of hypertension had an independent prognostic value for all-cause mortality in patients with COVID-19 who required hospitalization. ARBs showed a lower risk of lethality in hypertensive patients than other antihypertensive drugs. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

10 pages, 550 KiB

Open AccessArticle

The PANDEMYC Score. An Easily Applicable and Interpretable Model for Predicting Mortality Associated With COVID-19

by Juan Torres-Macho, Pablo Ryan, Jorge Valencia, Mario Pérez-Butragueño, Eva Jiménez, Mario Fontán-Vela, Elsa Izquierdo-García, Inés Fernandez-Jimenez, Elena Álvaro-Alonso, Andrea Lazaro, Marta Alvarado, Helena Notario, Salvador Resino, Daniel Velez-Serrano and Alejandro Meca

J. Clin. Med. 2020, 9(10), 3066; https://doi.org/10.3390/jcm9103066 - 23 Sep 2020

Cited by 29 | Viewed by 7787

Abstract

This study aimed to build an easily applicable prognostic model based on routine clinical, radiological, and laboratory data available at admission, to predict mortality in coronavirus 19 disease (COVID-19) hospitalized patients. Methods: We retrospectively collected clinical information from 1968 patients admitted to a [...] Read more.

This study aimed to build an easily applicable prognostic model based on routine clinical, radiological, and laboratory data available at admission, to predict mortality in coronavirus 19 disease (COVID-19) hospitalized patients. Methods: We retrospectively collected clinical information from 1968 patients admitted to a hospital. We built a predictive score based on a logistic regression model in which explicative variables were discretized using classification trees that facilitated the identification of the optimal sections in order to predict inpatient mortality in patients admitted with COVID-19. These sections were translated into a score indicating the probability of a patient’s death, thus making the results easy to interpret. Results. Median age was 67 years, 1104 patients (56.4%) were male, and 325 (16.5%) died during hospitalization. Our final model identified nine key features: age, oxygen saturation, smoking, serum creatinine, lymphocytes, hemoglobin, platelets, C-reactive protein, and sodium at admission. The discrimination of the model was excellent in the training, validation, and test samples (AUC: 0.865, 0.808, and 0.883, respectively). We constructed a prognostic scale to determine the probability of death associated with each score. Conclusions: We designed an easily applicable predictive model for early identification of patients at high risk of death due to COVID-19 during hospitalization. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Graphical abstract

10 pages, 1526 KiB

Open AccessArticle

Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19

by Luigi Brunetti, Oumou Diawara, Andrew Tsai, Bonnie L. Firestein, Ronald G. Nahass, George Poiani and Naomi Schlesinger

J. Clin. Med. 2020, 9(9), 2961; https://doi.org/10.3390/jcm9092961 - 14 Sep 2020

Cited by 63 | Viewed by 11830

Abstract

The repurposing of colchicine for the treatment of COVID-19 was suggested based in its immunomodulatory, anti-inflammatory, and anti-viral properties. We performed a single-center propensity score matched cohort study, including all consecutive COVID-19 patients admitted to a community hospital between 1 March 2020 and [...] Read more.

The repurposing of colchicine for the treatment of COVID-19 was suggested based in its immunomodulatory, anti-inflammatory, and anti-viral properties. We performed a single-center propensity score matched cohort study, including all consecutive COVID-19 patients admitted to a community hospital between 1 March 2020 and 30 May 2020. Patients were stratified according to the receipt of colchicine. The primary endpoint was defined as in-hospital death within 28-days follow-up. Secondary endpoints included favorable change in the Ordinal Scale for Clinical Improvement on days 14 and 28 versus baseline, proportion of patients not requiring supplemental oxygen on days 14 and 28, and proportion of patients discharged by day 28. In total data for 303 PCR positive COVID-19 patients were extracted and 66 patients were included in the 1:1 matched cohort study. At the end of the 28 day follow-up, patients receiving colchicine were approximately five times more likely to be discharged (odds ratio, 5.0; 95% confidence interval, 1.25–20.1; p = 0.023) and when comparing mortality, there were 3 deaths (9.1%) in patients receiving colchicine versus 11 deaths (33.3%) in the groups receiving standard of care (odds ratio, 0.20; 95% confidence interval, 0.05–0.80; p = 0.023). These observations warrant further investigation in large controlled clinical trials. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

13 pages, 646 KiB

Open AccessArticle

The Wide Spectrum of COVID-19 Clinical Presentation in Children

by Nadia Nathan, Blandine Prevost, Chiara Sileo, Nicolas Richard, Laura Berdah, Guillaume Thouvenin, Guillaume Aubertin, Thibault Lecarpentier, Aurélie Schnuriger, Julien Jegard, Isabelle Guellec, Jessica Taytard and Harriet Corvol

J. Clin. Med. 2020, 9(9), 2950; https://doi.org/10.3390/jcm9092950 - 12 Sep 2020

Cited by 33 | Viewed by 5126

Abstract

Background: Ten months after its appearance in December 2019, SARS-CoV-2 has infected more than 25 million patients worldwide. Because children were first identified as potential spreaders of the virus, schools were closed in several countries. However, it rapidly became evident that the number [...] Read more.

Background: Ten months after its appearance in December 2019, SARS-CoV-2 has infected more than 25 million patients worldwide. Because children were first identified as potential spreaders of the virus, schools were closed in several countries. However, it rapidly became evident that the number of hospitalized children infected by SARS-CoV-2 was dramatically lower than that of adults. To date, only hypotheses have been raised to explain this difference, so it is of great importance to describe the presentation of this disease among children. Here, we describe a wide spectrum of COVID-19 manifestation in children in a dedicated pediatric unit in France. Methods: Patients hospitalized with COVID-19 who were diagnosed on the basis of either positive SARS-CoV-2 RT-PCR in nasopharyngeal swabs and/or typical aspects in chest-computed tomography (CT) were included between March and May 2020 in Paris. Results: Twenty-three patients were included on the basis of positive RT-PCR (n = 20) and/or typical aspects in CT (n = 4). The median age was 4.9 years [0.1–17.6]. Patients were grouped by age (<2 years old: n = 14, 61%; 2–10 years old: n = 2, 9%; >10 years old: n = 7, 30%). Overweight or obesity was reported in only three patients. At presentation, the most frequent symptom in the overall cohort was fever (n = 18, 78%), followed by acute rhinitis (n = 9, 64%) and cough (n = 7, 50%) in the under 2-year-old group and cough (n = 4, 57%), fatigue, dyspnea and abdominal pain (n = 3, 43% each) in the over 10-year-old group. Five patients required ICU treatment, four of whom were aged >10 years, two presented with acute myocarditis, and two were sickle cell disease patients who presented with acute chest syndrome. Discussion and conclusion: The youngest patients seem to present milder forms of COVID-19 without the need for ICU treatment and with a shorter length of hospitalization. More severe evolutions were observed in teenagers, with, however, favorable outcomes. Given the context of closed schools and confinement, the infection of these children suggests intra-familial transmission that needs to be further assessed. This description might help to understand the intriguing differences in COVID-19 severity across age-classes. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

10 pages, 566 KiB

Open AccessArticle

The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients

by Marco Vicenzi, Massimiliano Ruscica, Simona Iodice, Irene Rota, Angelo Ratti, Roberta Di Cosola, Alberto Corsini, Valentina Bollati, Stefano Aliberti and Francesco Blasi

J. Clin. Med. 2020, 9(9), 2943; https://doi.org/10.3390/jcm9092943 - 11 Sep 2020

Cited by 15 | Viewed by 4258

Abstract

Background: In COVID-19 patients, aldosterone via angiotensin-converting enzyme-2 deregulation may be responsible for systemic and pulmonary vasoconstriction, inflammation, and oxidative organ damage. Aim: To verify retrospectively the impact of the mineralcorticoid receptor antagonist canrenone i.v. on the need of invasive ventilatory support and/or [...] Read more.

Background: In COVID-19 patients, aldosterone via angiotensin-converting enzyme-2 deregulation may be responsible for systemic and pulmonary vasoconstriction, inflammation, and oxidative organ damage. Aim: To verify retrospectively the impact of the mineralcorticoid receptor antagonist canrenone i.v. on the need of invasive ventilatory support and/or all-cause in-hospital mortality. Methods: Sixty-nine consecutive COVID-19 patients, hospitalized for moderate to severe respiratory failure at Fondazione Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca’ Granda Ospedale Maggiore Policlinico of Milan, received two different therapeutic approaches in usual care according to the personal skills and pharmacological management experience of the referral medical team. Group A (n = 39) were given vasodilator agents or renin–angiotensin–aldosterone system (RAAS) inhibitors and group B (n = 30) were given canrenone i.v. Results: Among the 69 consecutive COVID-19 patients, those not receiving canrenone i.v. (group A) had an event-free rate of 51% and a survival rate of 64%. Group B (given a mean dose of 200 mg/q.d. of canrenone for at least two days of continuous administration) showed an event-free rate of 80% with a survival rate of 87%. Kaplan–Meier analysis for composite outcomes and mortality showed log rank statistics of 0.0004 and 0.0052, respectively. Conclusions: The novelty of our observation relies on the independent positive impact of canrenone on the all-cause mortality and clinical improvement of COVID-19 patients ranging from moderate to severe diseases. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

11 pages, 688 KiB

Open AccessArticle

Autism and COVID-19: A Case Series in a Neurodevelopmental Unit

by Leslie Nollace, Cora Cravero, Alice Abbou, Brice Mazda-Walter, Alexandre Bleibtreu, Nathalie Pereirra, Myriam Sainte-Marie, David Cohen and Marianna Giannitelli

J. Clin. Med. 2020, 9(9), 2937; https://doi.org/10.3390/jcm9092937 - 11 Sep 2020

Cited by 17 | Viewed by 5234

Abstract

Background: COVID-19 has become pandemic and can impact individuals with autism as well. Here, we report a case series admitted to a neurobehavioral unit dedicated to challenging behaviors in patients with autism. Methods: We describe 16 patients (mean age 20.8 years; range 12–43 [...] Read more.

Background: COVID-19 has become pandemic and can impact individuals with autism as well. Here, we report a case series admitted to a neurobehavioral unit dedicated to challenging behaviors in patients with autism. Methods: We describe 16 patients (mean age 20.8 years; range 12–43 years; 76% male) with autism hospitalized between March 2020 and mid-April 2020 for challenging behaviors, for which COVID-19 disease has been suspected and who needed both psychiatric and medical care. A close cooperation with the Infectious and Tropical Diseases Department was organized to limit viral spread and training sessions (e.g., hygiene, clinical COVID-19 monitoring, virus testing) were given to staff members. Results: Most patients had severe autism and severe/moderate intellectual disability. Eleven patients were already in the unit when it was hit by the pandemic, and five were admitted from the community. Based on a virus search via reverse transcriptase polymerase chain reaction (RT-PCR) or serology at the 2-month follow-up, we had 11 confirmed COVID-19 cases. The main COVID-19 symptoms included benign upper respiratory infection signs (N = 9, 81.8%), diarrhea (N = 7, 63.6%), fatigue (N = 7, 63.6%), and respiratory signs (N = 5, 45.5%), including one patient who needed oxygen therapy. Three patients remained asymptomatic and COVID-19-free (including two under immunosuppressive treatments). Among the symptomatic patients, five showed atypical behaviors that we understood as idiosyncratic manifestations (e.g., irrepressible licking behavior). On day 14, only one patient with respiratory dysfunction still had a positive RT-PCR SARS-CoV-2 test. Conclusions: Organizing a COVID+ unit for patients with autism is realistic and requires close collaboration with infectologists. We believe that this initiative should be promoted to limit both the spread of the virus and the ostracism of patients with autism and challenging behaviors. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

9 pages, 1213 KiB

Open AccessArticle

Assessing Viral Shedding and Infectivity of Asymptomatic or Mildly Symptomatic Patients with COVID-19 in a Later Phase

by Yujin Sohn, Su Jin Jeong, Won Suk Chung, Jong Hoon Hyun, Yae Jee Baek, Yunsuk Cho, Jung Ho Kim, Jin Young Ahn, Jun Yong Choi and Joon-Sup Yeom

J. Clin. Med. 2020, 9(9), 2924; https://doi.org/10.3390/jcm9092924 - 10 Sep 2020

Cited by 47 | Viewed by 6934

Abstract

Background: The coronavirus disease (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a major global public health issue. SARS-CoV-2 infection is confirmed by the detection of viral RNA using reverse transcription polymerase chain reaction (RT-PCR). Prolonged viral shedding [...] Read more.

Background: The coronavirus disease (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a major global public health issue. SARS-CoV-2 infection is confirmed by the detection of viral RNA using reverse transcription polymerase chain reaction (RT-PCR). Prolonged viral shedding has been reported in patients with SARS-CoV-2 infection, but the presence of viral RNA does not always correlate with infectivity. Therefore, the present study aimed to confirm the presence of viable virus in asymptomatic or mildly symptomatic patients in the later phase of the disease, more than two weeks after diagnosis. Method: Asymptomatic or mildly symptomatic COVID-19 patients who had been diagnosed with the disease at least two weeks previously and admitted to a community treatment center (CTC) from 15 March to 10 April 2020 were enrolled in this study. Nasopharyngeal and salivary swab specimens were collected from each patient. Using these specimens, RT-PCR assay and viral culture were performed. Result: In total, 48 patients were enrolled in this study. There were no significant differences in baseline characteristics between the asymptomatic and mildly symptomatic patient groups. RT-PCR assay and viral culture of SARS-CoV-2 were performed using nasopharyngeal and salivary swabs. The results of RT-PCR performed using salivary swab specimens, in terms of cycle threshold (Ct) values, were similar to those of RT-PCR using nasopharyngeal swab specimens. In addition, no viable virus could be cultured from swab specimens collected from the late-phase COVID-19 patients with prolonged viral RNA shedding. Conclusions: In conclusion, our study suggests that even if viral shedding is sustained in asymptomatic or mildly symptomatic patients with later phase of COVID-19, it can be expected that the transmission risk of the virus is low. In addition, saliva can be used as a reliable specimen for the diagnosis of SARS-CoV-2 infection. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

10 pages, 481 KiB

Open AccessArticle

Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality in COVID-19

by Filippo Albani, Federica Fusina, Alessia Giovannini, Pierluigi Ferretti, Anna Granato, Chiara Prezioso, Danilo Divizia, Alessandra Sabaini, Marco Marri, Elena Malpetti and Giuseppe Natalini

J. Clin. Med. 2020, 9(9), 2800; https://doi.org/10.3390/jcm9092800 - 30 Aug 2020

Cited by 26 | Viewed by 6217

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has led to widespread use of hydroxychloroquine and azithromycin despite the lack of conclusive evidence for their safety and efficacy. We evaluated the association between treatment with hydroxychloroquine and/or azithromycin and hospital mortality as [...] Read more.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has led to widespread use of hydroxychloroquine and azithromycin despite the lack of conclusive evidence for their safety and efficacy. We evaluated the association between treatment with hydroxychloroquine and/or azithromycin and hospital mortality as the primary outcome. We compared the hospital mortality of patients treated with hydroxychloroquine alone, azithromycin alone, or their combination to the mortality of patients who received neither drug. A logistic multivariate model with overlap weight propensity score was used for estimation of odds ratios (ORs) with 95% confidence intervals (95% CIs). One thousand four hundred and three patients with SARS-CoV-2 infection were admitted to the hospital. At the time of the analysis, the outcome was available for 1376 (98%) of them. Five hundred and eighty-seven patients (42%) received azithromycin and 377 patients (27%) received hydroxychloroquine, alone or in combination. In-hospital mortality was 26%. After the adjusted analysis, azithromycin alone was associated with lower mortality (OR 0.60, 95% CI 0.42–0.85) compared to no treatment. Hydroxychloroquine alone (OR 0.76, 95% CI 0.53–1.08) and the combination of azithromycin and hydroxychloroquine (OR 1.13, 95% CI 0.77–1.69) were not associated with hospital mortality. In this cohort of patients, azithromycin alone was associated with lower hospital mortality but hydroxychloroquine was not associated with increased or reduced mortality. While we await randomized clinical trials, these data support the use of azithromycin in novel coronavirus disease 2019 (COVID-19) and can contribute to better understanding of its role in further meta-analyses. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

Review

Jump to: Research

10 pages, 935 KiB

Open AccessReview

Post-Acute COVID-19 Neurological Syndrome: A New Medical Challenge

by Domenico Nuzzo, Sonya Vasto, Luca Scalisi, Salvatore Cottone, Gaetano Cambula, Manfredi Rizzo, Daniela Giacomazza and Pasquale Picone

J. Clin. Med. 2021, 10(9), 1947; https://doi.org/10.3390/jcm10091947 - 1 May 2021

Cited by 39 | Viewed by 8801

Abstract

In December 2019, in Wuhan (China), a highly pathogenic coronavirus, named SARS-CoV-2, dramatically emerged. This new virus, which causes severe pneumonia, is rapidly spreading around the world, hence it provoked the COVID-19 pandemic. This emergency launched by SARS-CoV-2 also had, and still has, [...] Read more.

In December 2019, in Wuhan (China), a highly pathogenic coronavirus, named SARS-CoV-2, dramatically emerged. This new virus, which causes severe pneumonia, is rapidly spreading around the world, hence it provoked the COVID-19 pandemic. This emergency launched by SARS-CoV-2 also had, and still has, devastating socio-economic aspects. Assessing the impact of COVID-19 on vulnerable groups of people is crucial for the adaptation of governments’ responses. Growing scientific evidence suggests that it is essential to keep the attention on people after acute SARS-CoV-2 infection; indeed, some clinical manifestations are frequently present even after recovery. There is consensus on the need to define which symptoms persist after the infection and which disabilities may arise after COVID-19. Recent reviews, case reports, and original contributions suggest that various organs may be affected, and neurological symptoms are present in about one third of patients with COVID-19. Neurological complications after severe COVID-19 infection might include delirium, brain inflammation, stroke, and nerve damage. In the recent pandemic, neurologists and neurobiologists have a chance to study key features of infection neurology. Furthermore, the psychological impact of the pandemic should not be underestimated, although there is currently no definition for this condition. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

15 pages, 301 KiB

Open AccessReview

The Management of Children with Cancer during the COVID-19 Pandemic: A Rapid Review

by Matteo Amicucci, Angela Mastronuzzi, Italo Ciaralli, Federico Piccioni, Andreea Cristina Schiopu, Emanuela Tiozzo, Orsola Gawronski, Valentina Biagioli and Immacolata Dall’Oglio

J. Clin. Med. 2020, 9(11), 3756; https://doi.org/10.3390/jcm9113756 - 21 Nov 2020

Cited by 10 | Viewed by 4485

Abstract

Despite the fact that cancer patients seem to be at a higher risk of being infected with SARS-CoV-2, limited data are available in the pediatric oncology setting. A systematic rapid review was conducted to analyze scientific literature regarding the management, interventions, and strategies [...] Read more.

Despite the fact that cancer patients seem to be at a higher risk of being infected with SARS-CoV-2, limited data are available in the pediatric oncology setting. A systematic rapid review was conducted to analyze scientific literature regarding the management, interventions, and strategies adopted to prevent the spread of COVID-19 in the pediatric cancer population. Our search on PubMed, Scopus, Cochrane, and EMBASE databases yielded 505 articles. After removing duplicates, 21 articles were included. Articles focused on infection prevention (n = 19; 90.5%), management (n = 18; 85.7%), overall management of specific treatments for cancer (n = 13; 61.9%), and education (n = 7; 33.3%). The interventions adopted to prevent the spread of COVID-19 were similar across organizations and in line with general recommendations. Most of them reported interventions that could be used as valid strategies for similar emergencies. The strategies included limiting the risk of contagion by restricting access to the wards and implementing hygiene measures, the identification of separate pathways for the management of patients suspected or confirmed to be infected with COVID-19, the postponement of people accessing the hospital for non-urgent or unnecessary tests or medical examinations, and the preventive screening of patients before chemotherapy treatment or transplantation of hematopoietic stem cells. It is necessary to identify key indicators in order to better evaluate the effectiveness of the interventions implemented over time. A summary of the recommendations is provided. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

14 pages, 2139 KiB

Open AccessReview

Novel Evidence of Acute Kidney Injury in COVID-19

by Ti-I Chueh, Cai-Mei Zheng, Yi-Chou Hou and Kuo-Cheng Lu

J. Clin. Med. 2020, 9(11), 3547; https://doi.org/10.3390/jcm9113547 - 3 Nov 2020

Cited by 40 | Viewed by 4862

Abstract

The coronavirus 2019 (COVID-19) pandemic has caused a huge impact on health and economic issues. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes cellular damage by entry mediated by the angiotensin-converting enzyme 2 of the host cells and its conjugation with spike proteins [...] Read more.

The coronavirus 2019 (COVID-19) pandemic has caused a huge impact on health and economic issues. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes cellular damage by entry mediated by the angiotensin-converting enzyme 2 of the host cells and its conjugation with spike proteins of SARS-CoV-2. Beyond airway infection and acute respiratory distress syndrome, acute kidney injury is common in SARS-CoV-2-associated infection, and acute kidney injury (AKI) is predictive to multiorgan dysfunction in SARS-CoV-2 infection. Beyond the cytokine storm and hemodynamic instability, SARS-CoV-2 might directly induce kidney injury and cause histopathologic characteristics, including acute tubular necrosis, podocytopathy and microangiopathy. The expression of apparatus mediating SARS-CoV-2 entry, including angiotensin-converting enzyme 2, transmembrane protease serine 2 (TMPRSS2) and a disintegrin and metalloprotease 17 (ADAM17), within the renal tubular cells is highly associated with acute kidney injury mediated by SARS-CoV-2. Both entry from the luminal and basolateral sides of the renal tubular cells are the possible routes for COVID-19, and the microthrombi associated with severe sepsis and the dysregulated renin–angiotensin–aldosterone system worsen further renal injury in SARS-CoV-2-associated AKI. In the podocytes of the glomerulus, injured podocyte expressed CD147, which mediated the entry of SARS-CoV-2 and worsen further foot process effacement, which would worsen proteinuria, and the chronic hazard induced by SARS-CoV-2-mediated kidney injury is still unknown. Therefore, the aim of the review is to summarize current evidence on SARS-CoV-2-associated AKI and the possible pathogenesis directly by SARS-CoV-2. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

14 pages, 893 KiB

Open AccessReview

The Role of Molecular Chaperones in Virus Infection and Implications for Understanding and Treating COVID-19

by Letizia Paladino, Alessandra Maria Vitale, Celeste Caruso Bavisotto, Everly Conway de Macario, Francesco Cappello, Alberto J.L. Macario and Antonella Marino Gammazza

J. Clin. Med. 2020, 9(11), 3518; https://doi.org/10.3390/jcm9113518 - 30 Oct 2020

Cited by 30 | Viewed by 5906

Abstract

The COVID-19 pandemic made imperative the search for means to end it, which requires a knowledge of the mechanisms underpinning the multiplication and spread of its cause, the coronavirus SARS-CoV-2. Many viruses use members of the hosts’ chaperoning system to infect the target [...] Read more.

The COVID-19 pandemic made imperative the search for means to end it, which requires a knowledge of the mechanisms underpinning the multiplication and spread of its cause, the coronavirus SARS-CoV-2. Many viruses use members of the hosts’ chaperoning system to infect the target cells, replicate, and spread, and here we present illustrative examples. Unfortunately, the role of chaperones in the SARS-CoV-2 cycle is still poorly understood. In this review, we examine the interactions of various coronaviruses during their infectious cycle with chaperones in search of information useful for future research on SARS-CoV-2. We also call attention to the possible role of molecular mimicry in the development of autoimmunity and its widespread pathogenic impact in COVID-19 patients. Viral proteins share highly antigenic epitopes with human chaperones, eliciting anti-viral antibodies that crossreact with the chaperones. Both, the critical functions of chaperones in the infectious cycle of viruses and the possible role of these molecules in COVID-19 autoimmune phenomena, make clear that molecular chaperones are promising candidates for the development of antiviral strategies. These could consist of inhibiting-blocking those chaperones that are necessary for the infectious viral cycle, or those that act as autoantigens in the autoimmune reactions causing generalized destructive effects on human tissues. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

15 pages, 229 KiB

Open AccessReview

Impact of the COVID-19 Pandemic on Student and Resident Teaching and Training in Surgical Oncology

by Hans-Michael Hau, Jürgen Weitz and Ulrich Bork

J. Clin. Med. 2020, 9(11), 3431; https://doi.org/10.3390/jcm9113431 - 26 Oct 2020

Cited by 42 | Viewed by 4367

Abstract

The COVID-19 pandemic has tremendously changed private and professional interactions and behaviors worldwide. The effects of this pandemic and the actions taken have changed our healthcare systems, which consequently has affected medical education and surgical training. In the face of constant disruptions of [...] Read more.

The COVID-19 pandemic has tremendously changed private and professional interactions and behaviors worldwide. The effects of this pandemic and the actions taken have changed our healthcare systems, which consequently has affected medical education and surgical training. In the face of constant disruptions of surgical education and training during this pandemic outbreak, structured and innovative concepts and adapted educational curricula are important to ensure a high quality of medical treatment. While efforts were undertaken to prevent viral spreading, it is important to analyze and assess the effects of this crisis on medical education, surgical training and teaching at large and certainly in the field of surgical oncology. Against this background, in this paper we introduce practical and creative recommendations for the continuity of students’ and residents’ medical and surgical training and teaching. This includes virtual educational curricula, skills development classes, video-based feedback and simulation in the specialty field of surgical oncology. In conclusion, the effects of COVID 19 on Surgical Training and Teaching, certainly in the field of Surgical Oncology, are challenging. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

26 pages, 2877 KiB

Open AccessReview

Rapid Antibody-Based COVID-19 Mass Surveillance: Relevance, Challenges, and Prospects in a Pandemic and Post-Pandemic World

by Robin Augustine, Suvarthi Das, Anwarul Hasan, Abhilash S, Shaheen Abdul Salam, Priya Augustine, Yogesh Bharat Dalvi, Ruby Varghese, Rosita Primavera, Hadi Mohamad Yassine, Avnesh S. Thakor and Bhavesh D. Kevadiya

J. Clin. Med. 2020, 9(10), 3372; https://doi.org/10.3390/jcm9103372 - 21 Oct 2020

Cited by 53 | Viewed by 16697

Abstract

The aggressive outbreak of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) as COVID-19 (coronavirus disease-2019) pandemic demands rapid and simplified testing tools for its effective management. Increased mass testing and surveillance are crucial for controlling the disease spread, obtaining better pandemic statistics, and [...] Read more.

The aggressive outbreak of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) as COVID-19 (coronavirus disease-2019) pandemic demands rapid and simplified testing tools for its effective management. Increased mass testing and surveillance are crucial for controlling the disease spread, obtaining better pandemic statistics, and developing realistic epidemiological models. Despite the advantages of nucleic acid- and antigen-based tests such as accuracy, specificity, and non-invasive approaches of sample collection, they can only detect active infections. Antibodies (immunoglobulins) are produced by the host immune system within a few days after infection and persist in the blood for at least several weeks after infection resolution. Antibody-based tests have provided a substitute and effective method of ultra-rapid detection for multiple contagious disease outbreaks in the past, including viral diseases such as SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome). Thus, although not highly suitable for early diagnosis, antibody-based methods can be utilized to detect past infections hidden in the population, including asymptomatic ones. In an active community spread scenario of a disease that can provide a bigger window for mass detections and a practical approach for continuous surveillance. These factors encouraged researchers to investigate means of improving antibody-based rapid tests and employ them as reliable, reproducible, sensitive, specific, and economic tools for COVID-19 mass testing and surveillance. The development and integration of such immunoglobulin-based tests can transform the pandemic diagnosis by moving the same out of the clinics and laboratories into community testing sites and homes. This review discusses the principle, technology, and strategies being used in antibody-based testing at present. It also underlines the immense prospect of immunoglobulin-based testing and the efficacy of repeated planned deployment in pandemic management and post-pandemic sustainable screenings globally. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

24 pages, 3056 KiB

Open AccessReview

Repurposing Immunomodulatory Therapies against Coronavirus Disease 2019 (COVID-19) in the Era of Cardiac Vigilance: A Systematic Review

by Courtney M. Campbell, Avirup Guha, Tamanna Haque, Tomas G. Neilan and Daniel Addison

J. Clin. Med. 2020, 9(9), 2935; https://doi.org/10.3390/jcm9092935 - 11 Sep 2020

Cited by 9 | Viewed by 4681

Abstract

The ongoing coronavirus disease 2019 (COVID-19) pandemic has resulted in efforts to identify therapies to ameliorate adverse clinical outcomes. The recognition of the key role for increased inflammation in COVID-19 has led to a proliferation of clinical trials targeting inflammation. The purpose of [...] Read more.

The ongoing coronavirus disease 2019 (COVID-19) pandemic has resulted in efforts to identify therapies to ameliorate adverse clinical outcomes. The recognition of the key role for increased inflammation in COVID-19 has led to a proliferation of clinical trials targeting inflammation. The purpose of this review is to characterize the current state of immunotherapy trials in COVID-19, and focuses on associated cardiotoxicities, given the importance of pharmacovigilance. The search terms related to COVID-19 were queried in ClinicalTrials.gov. A total of 1621 trials were identified and screened for interventional trials directed at inflammation. Trials (n = 226) were fully assessed for the use of a repurposed drug, identifying a total of 141 therapeutic trials using a repurposed drug to target inflammation in COVID-19 infection. Building on the results of the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial demonstrating the benefit of low dose dexamethasone in COVID-19, repurposed drugs targeting inflammation are promising. Repurposed drugs directed at inflammation in COVID-19 primarily have been drawn from cancer therapies and immunomodulatory therapies, specifically targeted anti-inflammatory, anti-complement, and anti-rejection agents. The proposed mechanisms for many cytokine-directed and anti-rejection drugs are focused on evidence of efficacy in cytokine release syndromes in humans or animal models. Anti-complement-based therapies have the potential to decrease both inflammation and microvascular thrombosis. Cancer therapies are hypothesized to decrease vascular permeability and inflammation. Few publications to date describe using these drugs in COVID-19. Early COVID-19 intervention trials have re-emphasized the subtle, but important cardiotoxic sequelae of potential therapies on outcomes. The volume of trials targeting the COVID-19 hyper-inflammatory phase continues to grow rapidly with the evaluation of repurposed drugs and late-stage investigational agents. Leveraging known clinical safety profiles and pharmacodynamics allows swift investigation in clinical trials for a novel indication. Physicians should remain vigilant for cardiotoxicity, often not fully appreciated in small trials or in short time frames. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

17 pages, 1854 KiB

Open AccessReview

Racial Disparities-Associated COVID-19 Mortality among Minority Populations in the US

by Donald J. Alcendor

J. Clin. Med. 2020, 9(8), 2442; https://doi.org/10.3390/jcm9082442 - 30 Jul 2020

Cited by 231 | Viewed by 23307

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a betacoronavirus that causes the novel coronavirus disease 2019 (COVID-19), is highly transmissible and pathogenic for humans and may cause life-threatening disease and mortality, especially in individuals with underlying comorbidities. First identified in an outbreak in [...] Read more.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a betacoronavirus that causes the novel coronavirus disease 2019 (COVID-19), is highly transmissible and pathogenic for humans and may cause life-threatening disease and mortality, especially in individuals with underlying comorbidities. First identified in an outbreak in Wuhan, China, COVID-19 is affecting more than 185 countries and territories around the world, with more than 15,754,651 confirmed cases and more than 640,029 deaths. Since December 2019, SARS-CoV-2 transmission has become a global threat, which includes confirmed cases in all 50 states within the United States (US). As of 25 July 2020, the Johns Hopkins Whiting School of Engineering Center for Systems Science and Engineering reports more than 4,112,651 cases and 145,546 deaths. To date, health disparities are associated with COVID-19 mortality among underserved populations. Here, the author explores potential underlying reasons for reported disproportionate, increased risks of mortality among African Americans and Hispanics/Latinos with COVID-19 compared with non-Hispanic Whites. The author examines the underlying clinical implications that may predispose minority populations and the adverse clinical outcomes that may contribute to increased risk of mortality. Government and community-based strategies to safeguard minority populations at risk for increased morbidity and mortality are essential. Underserved populations living in poverty with limited access to social services across the US are more likely to have underlying medical conditions and are among the most vulnerable. Societal and cultural barriers for ethnic minorities to achieve health equity are systemic issues that may be addressed only through shifts in governmental policies, producing long-overdue, substantive changes to end health care inequities. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

19 pages, 1951 KiB

Open AccessReview

Vaccines and Therapies in Development for SARS-CoV-2 Infections

by David Wu, Raghuram Koganti, Upendra P. Lambe, Tejabhiram Yadavalli, Shyam S. Nandi and Deepak Shukla

J. Clin. Med. 2020, 9(6), 1885; https://doi.org/10.3390/jcm9061885 - 16 Jun 2020

Cited by 40 | Viewed by 10102

Abstract

The current COVID-19 pandemic is caused by the novel coronavirus SARS-CoV-2. The virus causes severe respiratory symptoms which manifest disproportionately in the elderly. Currently, there are over 6.5 million cases and 380,000 deaths reported. Given the current severity of the outbreak, there is [...] Read more.

The current COVID-19 pandemic is caused by the novel coronavirus SARS-CoV-2. The virus causes severe respiratory symptoms which manifest disproportionately in the elderly. Currently, there are over 6.5 million cases and 380,000 deaths reported. Given the current severity of the outbreak, there is a great need for antiviral therapies and vaccines to treat and prevent COVID-19. In this review, we provide an overview of SARS-CoV-2 and discuss the emerging therapies and vaccines that show promise in combating COVID-19. We also highlight potential viral targets that could be exploited by researchers and drug manufacturers. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

22 pages, 1529 KiB

Open AccessReview

COVID-19: Specific and Non-Specific Clinical Manifestations and Symptoms: The Current State of Knowledge

by Jacek Baj, Hanna Karakuła-Juchnowicz, Grzegorz Teresiński, Grzegorz Buszewicz, Marzanna Ciesielka, Ryszard Sitarz, Alicja Forma, Kaja Karakuła, Wojciech Flieger, Piero Portincasa and Ryszard Maciejewski

J. Clin. Med. 2020, 9(6), 1753; https://doi.org/10.3390/jcm9061753 - 5 Jun 2020

Cited by 275 | Viewed by 23997

Abstract

Coronavirus disease 2019 (COVID-19), due to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become an epidemiological threat and a worldwide concern. SARS-CoV-2 has spread to 210 countries worldwide and more than 6,500,000 confirmed cases and 384,643 deaths have been reported, while the [...] Read more.

Coronavirus disease 2019 (COVID-19), due to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become an epidemiological threat and a worldwide concern. SARS-CoV-2 has spread to 210 countries worldwide and more than 6,500,000 confirmed cases and 384,643 deaths have been reported, while the number of both confirmed and fatal cases is continually increasing. COVID-19 is a viral disease that can affect every age group—from infants to the elderly—resulting in a wide spectrum of various clinical manifestations. COVID-19 might present different degrees of severity—from mild or even asymptomatic carriers, even to fatal cases. The most common complications include pneumonia and acute respiratory distress syndrome. Fever, dry cough, muscle weakness, and chest pain are the most prevalent and typical symptoms of COVID-19. However, patients might also present atypical symptoms that can occur alone, which might indicate the possible SARS-CoV-2 infection. The aim of this paper is to review and summarize all of the findings regarding clinical manifestations of COVID-19 patients, which include respiratory, neurological, olfactory and gustatory, gastrointestinal, ophthalmic, dermatological, cardiac, and rheumatologic manifestations, as well as specific symptoms in pediatric patients. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

15 pages, 2693 KiB

Open AccessReview

Point-of-Care Diagnostic Tests for Detecting SARS-CoV-2 Antibodies: A Systematic Review and Meta-Analysis of Real-World Data

by Matteo Riccò, Pietro Ferraro, Giovanni Gualerzi, Silvia Ranzieri, Brandon Michael Henry, Younes Ben Said, Natalia Valeryevna Pyatigorskaya, Elena Nevolina, Jianhong Wu, Nicola Luigi Bragazzi and Carlo Signorelli

J. Clin. Med. 2020, 9(5), 1515; https://doi.org/10.3390/jcm9051515 - 18 May 2020

Cited by 65 | Viewed by 11315

Abstract

SARS-CoV-2 is responsible for a highly contagious infection, known as COVID-19. SARS-CoV-2 was discovered in late December 2019 and, since then, has become a global pandemic. Timely and accurate COVID-19 laboratory testing is an essential step in the management of the COVID-19 outbreak. [...] Read more.

SARS-CoV-2 is responsible for a highly contagious infection, known as COVID-19. SARS-CoV-2 was discovered in late December 2019 and, since then, has become a global pandemic. Timely and accurate COVID-19 laboratory testing is an essential step in the management of the COVID-19 outbreak. To date, assays based on the reverse-transcription polymerase chain reaction (RT-PCR) in respiratory samples are the gold standard for COVID-19 diagnosis. Unfortunately, RT-PCR has several practical limitations. Consequently, alternative diagnostic methods are urgently required, both for alleviating the pressure on laboratories and healthcare facilities and for expanding testing capacity to enable large-scale screening and ensure a timely therapeutic intervention. To date, few studies have been conducted concerning the potential utilization of rapid testing for COVID-19, with some conflicting results. Therefore, the present systematic review and meta-analysis was undertaken to explore the feasibility of rapid diagnostic tests in the management of the COVID-19 outbreak. Based on ten studies, we computed a pooled sensitivity of 64.8% (95%CI 54.5–74.0), and specificity of 98.0% (95%CI 95.8–99.0), with high heterogeneity and risk of reporting bias. We can conclude that: (1) rapid diagnostic tests for COVID-19 are necessary, but should be adequately sensitive and specific; (2) few studies have been carried out to date; (3) the studies included are characterized by low numbers and low sample power, and (4) in light of these results, the use of available tests is currently questionable for clinical purposes and cannot substitute other more reliable molecular tests, such as assays based on RT-PCR. Full article

(This article belongs to the Special Issue Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives)

► Show Figures

Figure 1

Journal Menu

Journal Browser

Coronavirus Disease 2019 (COVID-19) Pandemic: Current Knowledge and Future Perspectives

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Benefits of Publishing in a Special Issue

Published Papers (35 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI